Overview

Glargine Dosing in Hospitalized Patients With Type 2 Diabetes and Renal Insufficiency

Status:
Completed
Trial end date:
2011-06-30
Target enrollment:
Participant gender:
Summary
It is imperative to devise easy to follow, yet appropriate, guidelines for insulin use in renal-impaired patients. This will be done by comparing two regimens: 1) glargine once daily plus mealtime glulisine based on weight alone and 2) a predetermined dosing reduction algorithm with glargine/glulisine based on weight with reduction for decreased estimated GFR by MDRD as follows: < 30 ml/min/1.73m2 or on dialysis reduce dose by 50% from weight based calculation.
Phase:
Phase 4
Details
Lead Sponsor:
Loyola University
Collaborator:
Sanofi
Treatments:
Insulin
Insulin Glargine
Insulin glulisine
Insulin, Globin Zinc